Amarin Says REDUCE-IT Results Are Off Limits To Omega-3 Supplement Claims
REDUCE-IT results are limited to Amarin's Vascepa "and cannot be extrapolated to omega-3 products that are materially different based on, for example, composition, dosage, and regulatory status," pharma firm says in complaints against Coromega and Omax. Amarin seeks to stifle the omega-3 supplement firms despite First Amendment argument it made in successful litigation against FDA to make truthful statements about its products even though the information is not approved by the agency.
Cardiovascular benefits Amarin Corp. PLC recently reported for its prescription triglyceride-lowering fish oil from the REDUCE-IT trial were so encouraging that two omega-3 dietary supplement marketers couldn't resist linking their own products to them. Hands off, Amarin effectively declares in complaints seeking to block such actions.
Amarin's response to advertising by Coromega Health Inc. and Omax Health Inc. reflects typical pharma industry interest in protecting research...